Israeli-American Scientist Wins 2016 Eppendorf & Science Prize
The Israeli-American scientist Gilad Evrony, MD, PhD has won the 2016 Eppendorf & Science Prize for Neurobiology for his work on developing technologies to sequence and analyse the genomes of single cells from the human brain. Dr Evrony’s research, performed at Boston Children’s Hospital and Harvard Medical School with Dr Christopher Walsh and colleagues, has revealed a diversity of mutations in neuronal genomes indicating that every neuron in the brain carries a unique fingerprint of somatic mutations. Such mutations can cause focal brain malformations and may have a role in other unsolved neurologic diseases. The technology also allows, for the first time, reconstruction of developmental lineage trees in the human brain to study how cells proliferate and migrate to build the brain. Gilad Evrony received his undergraduate degree from the Massachusetts Institute of Technology. He served in the Intelligence Division of the Israel Defense Forces and completed an MD and PhD at Harvard Medical School, with graduate research in the laboratory
of Dr Christopher Walsh at Boston Children’s Hospital. Dr Evrony is currently pursuing clinical training in paediatrics at Mount Sinai Hospital in New York and continuing his research developing novel technologies for studying the brain and neuropsychiatric diseases. The annual US$25,000 Eppendorf & Science Prize for Neurobiology honours scientists, like Dr Evrony, for their ground-breaking research. Gilad Evrony is the 15th recipient of this international award which is awarded jointly by Eppendorf and the journal Science. Researchers who are not older than 35 years and have made outstanding contributions to neurobiological research based on methods of molecular and cell biology are invited to apply. The next deadline for applications is 15th June, 2017. For more information about Dr Evrony and the Prize, visit
www.eppendorf.com/prize
41107pr@reply-direct.com
Medical Research Projects Receive £1 million
Grants totalling £1 million for medical research projects in low and middle income countries (LMICs), have been awarded to researchers from the Queen Mary University of London (QMUL). Funded by the UK Research Council, the grants come from the first £20 million tranche of awards from the new Global Challenges Research Fund, which aims to address issues affecting people in LMICs using the UK’s world-class research expertise.
QMUL medical researchers were successful in all three of their applications to the fund, covering malnutrition, tuberculosis and respiratory disease research projects in Africa. One of the leading causes of deterioration and death in children with severe acute malnutrition is a condition known as ‘malnutrition enteropathy’, where the intestine is unable to exclude bacteria from entering the blood. Professor Paul Kelly will be testing out five novel treatments for the condition in children in Zambia and Zimbabwe.
Professor Adrian Martineau will set up a research study in
Ethiopia, a country with the tenth highest burden of human tuberculosis in the world. The project will evaluate a new test for dormant TB infection, which is very common in LMICs and has the potential to re-activate to cause the disease.
Along with colleagues at the Liverpool School of Tropical Medicine, Professor Jonathan Grigg received funding for the ‘Lung Health In Africa’ study which will be a pan- African platform for health research into non-communicable respiratory disease.
Professor Steve Thornton, Vice Principal (Health) at QMUL’s School of Medicine and Dentistry, said: “We are delighted with the award of these grants. The funds will help us to continue to apply our world-class research expertise to tackle the ever increasing global research challenges and improve the health of people in low and middle income countries.”
41511pr@reply-direct.com
Networking at Pittcon
The Pittcon Organising Committee has recently released the topics for Conferee Networking during Pittcon 2017, which will be in Chicago, Illinois, 5-9th March. Conferee Networking sessions provide an informal venue for a small group of participants to connect and openly discuss topics of mutual interest.
This year, there will be 34 facilitated sessions during Conference week covering topics related to food science, analytical methods, environmental science, nanoscience, biomedical, laboratory Information/data analysis, pharmaceutical science, lab safety and more. These 90-minute networking opportunities begin on Sunday and run through Wednesday afternoon and are open to all registered conferees at no extra cost.
Topics will include;
• Cannabis Testing Forum: New opportunities for enhancing quality and expanding research.
• Nanoscience and Nanotechnology (NANT) Education Strathclyde Joins the Cockcroft Institute leading research accelerators for the future.
Professor Peter Ratoff, Director of the Cockcroft Institute said: “The University of Strathclyde has a long and impressive history of world leading accelerator technology and has worked collaboratively with the Cockcroft Institute as an Associate Member for a number of years. Now, as a full member, this further cements our collaborative relationship and strengthens our long term plans for next generation accelerator technologies that advance the impact of our research in healthcare, security, manufacturing and energy.”
The University of Strathclyde is home to the Scottish Centre for the Application of Plasma-based Accelerators (SCAPA), delivering research on next-generation accelerators and radiation technology.
The Cockcroft Institute Board. Back row, L to R: Professor S Watts (Manchester), Professor R McGrath (Liverpool), Professor S Decent (Lancaster), Professor G Blair (STFC) Front row, L to R: Professor P Ratoff (Director, Cockcroft), Professor K Badcock (Liverpool, Chair), Professor D Uttamchandani (Strathclyde). (Credit: STFC)
The Cockcroft Institute, the UK’s international centre for Accelerator Science and Technology at Sci-Tech Daresbury, Cheshire, has welcomed the University of Strathclyde as a full member. A joint venture between the Universities of Lancaster, Liverpool and Manchester and the Science and Technology Facilities Council (STFC), the Cockcroft Institute delivers world class research and development, positioning the UK in a major role for innovating future tools for scientific discoveries and in the conception, design, construction and use of the world’s
Professor Sir Jim McDonald, Principal and Vice-Chancellor of the University of Strathclyde, said: “The Cockcroft Institute is at the forefront of innovative, impactful research into accelerator technology, which has significant applications in health, energy and security. Over recent years, we have enjoyed a productive scientific partnership with the Institute so we are delighted to confirm our growing collaboration.
High profile projects underway at the Cockcroft Institute include a major ground breaking R&D programme in light sources at STFC’s Daresbury Laboratory, as well as upgrades to the Large Hadron Collider at CERN and development of technology for Sweden’s European Spallation Source, which is currently under construction.
41514pr@reply-direct.com
• The Importance of Particle Shape Information in the Pharmaceutical Product Quality Control Process
• Detection of Drug Consumption in Human Breath
• Non-Invasive Biomedical Analysis –VOCs Are in the Air-From Cellular Matabolism to Crown Monitoring
• Defining, Refining and Advancing Chemical Measurement and Imaging
• Assuring Water Quality
For a complete list and schedule visit
www.pittcon.org 41512pr@reply-direct.com
TO BE INCLUDED IN OUR NEXT ISSUE, SEND ALL YOUR RESEARCH AND EVENTS
NEWS STORIES TO: HEATHER@
INTLABMATE.COM
TO BE INCLUDED IN OUR NEXT ISSUE, SEND ALL YOUR RESEARCH AND EVENTS NEWS STORIES TO
HEATHER@INTLABMATE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
